• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/27/25 4:26:08 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    kvue-20250522
    0001944048false00019440482025-05-222025-05-22

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): May 22, 2025
    Kenvue Inc.
     (Exact name of registrant as specified in its charter)
    Delaware001-4169788-1032011
    (State or other jurisdiction
     of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    1 Kenvue Way
    Summit, New Jersey
    07901
    (Address of principal executive offices)(Zip Code)
    Registrant's telephone number, including area code: (908)-874-1200
    Not applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.01 par value per shareKVUENew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.07    Submission of Matters to a Vote of Security Holders.


    (a)     Kenvue Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders on May 22, 2025. For more information on the following proposals, see the Company’s proxy statement for the 2025 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission on April 9, 2025 (the “2025 Proxy Statement”).

    (b)     The final voting results of the matters presented at the 2025 Annual Meeting of Shareholders are set forth below.

    1.    Proposal 1 — Election of Directors.

    Shareholders elected all 13 director nominees named in the 2025 Proxy Statement to the Company’s Board of Directors to serve until the Company’s 2026 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, or until such director’s earlier death, resignation, disqualification or removal.
    Director NomineeForAgainstAbstainBroker Non-Votes
    Richard E. Allison, Jr.1,723,787,471 2,260,212 1,046,822 78,329,335 
    Seemantini Godbole1,713,346,215 12,769,148 979,142 78,329,335 
    Melanie L. Healey1,580,594,153 145,530,502 969,850 78,329,335 
    Sarah Hofstetter1,628,023,193 98,179,559 891,753 78,329,335 
    Betsy D. Holden1,701,067,330 25,057,703 969,472 78,329,335 
    Erica L. Mann1,718,333,086 7,835,567 925,852 78,329,335 
    Larry J. Merlo1,443,007,697 283,085,631 1,001,177 78,329,335 
    Thibaut Mongon1,665,869,004 60,164,246 1,061,255 78,329,335 
    Kathleen M. Pawlus1,724,367,909 1,764,058 962,538 78,329,335 
    Kirk L. Perry1,720,958,678 5,163,854 971,973 78,329,335 
    Vasant Prabhu1,723,609,636 2,444,048 1,040,821 78,329,335 
    Jeffrey C. Smith1,723,228,944 2,818,862 1,046,699 78,329,335 
    Michael E. Sneed1,723,865,435 2,262,298 966,772 78,329,335 


    2.    Proposal 2 — Approve, on a Non-Binding Advisory Basis, Named Executive Officer Compensation.

    Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
    ForAgainstAbstainBroker Non-Votes
    1,675,645,180 49,702,881 1,746,444 78,329,335 
        
        

    3.    Proposal 3 — Ratify the Appointment of the Company’s Independent Registered Public Accounting Firm for 2025.

    Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2025.
    ForAgainstAbstain
    1,801,996,331 2,585,780 841,729 





    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    KENVUE INC.
    Date: May 27, 2025By:/s/ Edward J. Reed
      Name:
    Title:
    Edward J. Reed
    Vice President, Corporate Secretary

    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    1/30/2026$18.00Buy → Hold
    Jefferies
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    More analyst ratings

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operations Officer Stevens Meredith converted options into 5,170 shares and covered exercise/tax liability with 2,096 shares, increasing direct ownership by 3% to 93,621 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:51 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Chief People Officer Alvarado Luani converted options into 4,222 shares and covered exercise/tax liability with 2,078 shares, increasing direct ownership by 4% to 61,415 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:44 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Group President EMEA & LA Lawson Carlton converted options into 6,158 shares, increasing direct ownership by 6% to 111,415 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    3/12/26 7:14:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

    Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ:KMB) and Kenvue Inc. (NYSE:KVUE) today announced that Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve all of the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue at their respective Special Meetings of Stockholders held today. "We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combina

    1/29/26 9:27:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    $KVUE
    SEC Filings

    View All

    SEC Form 10-K filed by Kenvue Inc.

    10-K - Kenvue Inc. (0001944048) (Filer)

    2/20/26 7:13:06 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    2/17/26 4:46:12 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    2/17/26 10:26:21 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Jefferies with a new price target

    Jefferies downgraded Kenvue from Buy to Hold and set a new price target of $18.00

    1/30/26 6:43:10 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary